Journal of chemotherapy
-
Journal of chemotherapy · Jan 2015
Comparative StudyPharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia.
To compare the pharmaceutical quality of original and generic ceftriaxone sodium preparations for injection produced in Eastern Asia. ⋯ All tested generic ceftriaxone products failed to meet the pharmaceutical quality standards of the branded original. The high levels of impurities and the identified contamination of particles and residues are of clinical concern, as they could impact tolerability and safety in patients in need of an effective parenteral antibiotic.
-
Journal of chemotherapy · Oct 2014
Multicenter StudyLapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Lapatinib is the first dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2/neu) and epidermal growth factor receptor (EGFR). The present study evaluated the efficacy and tolerability of the combination of lapatinib and capecitabine in patients with metastatic breast cancer (MBC) who progressed after therapy with trastuzumab, a taxane and/or anthracycline. A total of 203 patients with a median age of 48 years (range: 25-82 years) were evaluated retrospectively in 11 centres between September 2007 and May 2011. ⋯ There were no symptomatic cardiac events. Lapatinib and capecitabine combination therapy is effective and well tolerated in patients with MBC who had progressive disease after trastuzumab, taxane, and/or anthracycline therapy, as evidenced by this retrospective evaluation. Toxicity was mild to moderate with low grade 3-4 toxicity.
-
Journal of chemotherapy · Jun 2014
Case ReportsAcute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma.
Jehovah's witnesses represent a unique group of patients whose religious beliefs prohibit receiving transfusion of all blood products. Since most chemotherapeutic regimens used to treat acute leukemia are myelosuppressive and often resulting in potentially life threatening pancytopenia, their refusal of blood products poses a challenge to clinicians. We report a case of a Jehovah's Witness patient with acute lymphoblastic leukemia (ALL) who was successfully treated with non-myelosuppressive chemotherapy for both first and second remission and achieved complete remissions both times without transfusion of blood products.
-
Journal of chemotherapy · Jun 2014
The quality of life in patients during intravesical treatment and correlation with local symptoms.
To evaluate the quality of life (QoL) in patients who had undergone intravesical treatment for non-muscle invasive bladder cancer and analyse the correlation between QoL and local symptoms. ⋯ Long-term intravesical treatment could decline the QoL of patients. Local symptom was an important factor found to be associated with impairment of QoL. Appropriate therapy for local symptoms might improve the patients' overall QoL.
-
Journal of chemotherapy · Dec 2013
Observational StudyClinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
To explore clinical outcomes and cardiac safety of continuous antiHer2 therapy. ⋯ Continuous antiHer2 therapy provides good clinical outcomes, especially in those patients who received lapatinib. Cardiac dysfunction was a rare event, reversible, associated to trastuzumab and not related to treatment duration.